BiotechTube

Placebo + ARD-101

Phase 3Active
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphagia

Conditions

Hyperphagia, Prader-Willi Syndrome

Trial Timeline

Dec 20, 2024 → Apr 1, 2026

NCT ID
NCT06828861

About Placebo + ARD-101

Placebo + ARD-101 is a phase 3 stage product being developed by Aardvark Therapeutics for Hyperphagia. The current trial status is active. This product is registered under clinical trial identifier NCT06828861. Target conditions include Hyperphagia, Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06828861Phase 3Active

Competing Products

3 competing products in Hyperphagia

See all competitors
ProductCompanyStageHype Score
CarbetocinAcadia PharmaceuticalsPhase 3
72
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
ARD-101Aardvark TherapeuticsPhase 3
69

Other Products from Aardvark Therapeutics

ARD-101Phase 3
69
ARD-101Phase 2
44
Low Dose ARD-501 + High Dose ARD-501 + PlaceboPhase 2
44
ARD-101Phase 2
44
ARD-101 + PlaceboPhase 2
44